Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.32 |
| ▸ | SKP1 | P63208 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.32 |
| ▸ | FPR3 | P25089 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19828045 | 0.82 | GAA (0.46) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL17802123 | 0.79 | CYP11B2 (0.44) | — | |
| SCHEMBL17814138 | 0.74 | CYP11B2 (0.42) | GAA | |
| SCHEMBL16809886 | 0.74 | GAA (0.45) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL29918940 | 0.74 | GAA (0.45) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL3161721 | 0.74 | GAA (0.45) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL17802103 | 0.73 | CCNC (0.43) | — | |
| SCHEMBL19828043 | 0.72 | GAA (0.46) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL14861548 | 0.72 | GAA (0.61) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL17802140 | 0.72 | CYP11B2 (0.35) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| EP-3227300-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| WO-2016089800-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089800-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, CYP11B2 | GAA 1243/4885NFKB1 1205/4885NFKB2 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.